Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HanchorBioTPE:7827 -0.32%9 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates TPE:7827 with a GF Score™ of 9/100. Among 943 Biotechnology companies, HanchorBio ranks worse than 60.45% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. HanchorBio's EBITDA for the
three
months ended in Mar. 2026 was NT$-310.8 Mil. HanchorBio's Revenue for the
three
months ended in Mar. 2026 was NT$0.0 Mil. Therefore, HanchorBio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HanchorBio EBITDA Margin % Related Terms
HanchorBio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HanchorBio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:7827 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, HanchorBio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HanchorBio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HanchorBio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HanchorBio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HanchorBio (TPE:7827) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HanchorBio and its competitors. According to the industry distribution chart, HanchorBio ranks #570 out of 943 companies in the Biotechnology industry, placing it in the top 60.4%.
Is HanchorBio's EBITDA Margin % too high?
HanchorBio's current EBITDA Margin % is 0.00%. Based on the distribution chart, HanchorBio ranks #570 out of 943 companies in the Biotechnology industry, which is below the industry midpoint. Overall, HanchorBio has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does HanchorBio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, HanchorBio ranks #570 out of 943 companies for EBITDA Margin %. This places HanchorBio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HanchorBio and its competitors. HanchorBio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HanchorBio stock overvalued right now?
HanchorBio (TPE:7827) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. HanchorBio's overall GF Score™ is 9/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HanchorBio (TPE:7827), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
HanchorBio Inc through its subsidiaries, is conducting research and development of new anti-cancer drugs, utilizing an Fc-based biopharmaceutical platform technology to reactivate the immune system in the fight against disease. The core technology of HanchorBio is the FBDB (Fc-Based Designer Biologics) platform, which focuses on the development of next-generation immuno-oncology fusion protein therapeutics. This platform utilizes the antibody Fc region as a backbone, onto which various engineered anti-cancer molecules are constructed through protein engineering. Combined with AI-assisted drug design capabilities, this technology is dedicated to overcoming key challenges in tumor immunotherapy.
9GF Score
Get the complete analysis for TPE:7827
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7827 has been successfully added to your 
